2024
Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review
de Beur S, Dahir K, Imel E, Zanchetta M, Williams A, Li Z, Webb N, Crowe V, Johnson B, Carpenter T. Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: 102-113. PMID: 38913723, PMCID: PMC11651676, DOI: 10.1210/clinem/dgae431.Peer-Reviewed Original ResearchTumor-induced osteomalaciaHealthcare resource useResection outcomesCase reportHigher probability of tumor recurrenceSecrete fibroblast growth factor 23Probability of tumor recurrenceAssociated with tumor-induced osteomalaciaFibroblast growth factor 23Symptoms to diagnosisHealthcare resource burdenTumor recurrenceParaneoplastic syndromeTumor resectionAssociated with greater usePharmacological treatmentDisease characteristicsImaging testsPatientsMusculoskeletal symptomsTargeted literature reviewResource useOrthopedic surgeryProgressive disabilityMean time
1995
Secretion of a Large Molecular‐Weight Form of Insulin‐Like Growth Factor by a Primary Renal Tumor
Korn E, van Hoff J, Buckley P, Daughaday W, Carpenter T. Secretion of a Large Molecular‐Weight Form of Insulin‐Like Growth Factor by a Primary Renal Tumor. Pediatric Blood & Cancer 1995, 24: 392-396. PMID: 7715546, DOI: 10.1002/mpo.2950240610.Peer-Reviewed Original ResearchConceptsPrimary renal tumorsIGF-IIRenal tumorsInsulin-like growth factor-II levelsInsulin-like growth factorIGF-II contentPost-operative serumTotal IGF-IIFactor II levelsPediatric renal tumorsLarge molecular weight formsPreoperative serumAbdominal massTumor resectionII levelsBiochemical hypoglycemiaHypoglycemiaTumor tissueTumorsGrowth factorResectionMolecular weight formsSerumPatientsHistology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply